BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17070905)

  • 1. Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays.
    Merkerova M; Bruchova H; Brdicka R
    Leuk Res; 2007 May; 31(5):661-72. PubMed ID: 17070905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L; Savranskaya L; Sweatman TW
    Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization and prognostic significance of FLT3 in CML progression.
    Kim KI; Park J; Ahn KS; Won NH; Kim BK; Shin WG; Yoon SS; Oh JM
    Leuk Res; 2010 Aug; 34(8):995-1001. PubMed ID: 20031210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
    FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
    Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
    Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JNK2 and p38 MAPK over-expressions do not represent key events in chronic myeloid leukemia transformation.
    Merkerova M; Bruchova H; Brdicka R
    Neoplasma; 2007; 54(6):503-10. PubMed ID: 17949234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
    Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
    Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
    Bao F; Polk P; Nordberg ML; Veillon DM; Sun A; Deininger M; Murray D; Andersson BS; Munker R
    Leuk Res; 2007 Nov; 31(11):1511-20. PubMed ID: 17403535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.